(D-Ala2)-GIP (human)
(Synonyms: D-ALA2]-GIP(HUMAN)-胃抑素) 目录号 : GA20063
(D-Ala2)-GIP (human)是一种葡萄糖依赖性促胰岛素多肽的类似物，可激活GIP受体的活性（EC50=630pM），常用于研究II型糖尿病的治疗方法。
Cas No.:444073-04-5
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
(D-Ala2)-GIP (human) is an analog of glucose-dependent insulinotropic polypeptide that activates the GIP receptor (EC50=630pM) and is commonly used in research on type 2 diabetes treatment[1]. (D-Ala2)-GIP is resistant to degradation by dipeptidyl peptidase-4, thereby prolonging (D-Ala2)-GIP in vivo half-life and enhancing its insulin-secreting activity[2]. (D-Ala2)-GIP can modulate cellular energy metabolism, fat storage, and β-cell function[3]. (D-Ala2)-GIP also has the potential to ameliorate obesity-related insulin resistance and protect β-cells[4].
In vitro, pretreatment of mouse primary cardiomyocytes with (D-Ala2)-GIP (300nM) for 1 hour, followed by stimulation with 30mM high glucose for 24 hours, significantly suppressed NADPH oxidase-driven superoxide generation and reduced mRNA expression levels of the cardiac hypertrophy marker β-Mhc and the key fibrotic factor Tgf-β2[5]. Pretreatment of 3T3-L1 preadipocytes with (D-Ala2)-GIP (1μM) for 96 hours significantly promoted adipocyte differentiation and lipid accumulation, while upregulating gene expression of lipoprotein lipase (Lpl) and fatty acid synthase (Fasn)[6].
In vivo, daily intraperitoneal injection of (D-Ala2)-GIP (25nmol/kg) for 42 days in high-fat diet-induced obese, prediabetic Swiss NIH mice significantly reduced non-fasting blood glucose levels and improved glucose tolerance[7]. Daily intraperitoneal injection of (D-Ala2)-GIP (25nmol/kg) for 8 weeks in APPswe/PS1 Alzheimer's disease model mice significantly improved spatial memory and synaptic plasticity, increased synaptic density in the hippocampus, reduced amyloid plaque load and neuroinflammation, and enhanced neural progenitor cell proliferation in the dentate gyrus[8].
References:
[1] Hinke SA, Gelling RW, Pederson RA, et al. Dipeptidyl peptidase IV-resistant [D-Ala(2)]glucose-dependent insulinotropic polypeptide (GIP) improves glucose tolerance in normal and obese diabetic rats. Diabetes. 2002 Mar;51(3):652-61.
[2] Gault VA, Porter DW, Irwin N, Patel S, et al. Comparison of sub-chronic metabolic effects of stable forms of naturally occurring GIP(1-30) and GIP(1-42) in high-fat fed mice. J Endocrinol. 2011 Mar;208(3):265-71.
[3] Mansur SA, Mieczkowska A, Bouvard B, et al. Stable Incretin Mimetics Counter Rapid Deterioration of Bone Quality in Type 1 Diabetes Mellitus. J Cell Physiol. 2015 Dec;230(12):3009-18.
[4] Porter DW, Irwin N, Flatt PR, et al. Prolonged GIP receptor activation improves cognitive function, hippocampal synaptic plasticity and glucose homeostasis in high-fat fed mice. Eur J Pharmacol. 2011 Jan 15;650(2-3):688-93.
[5] Hiromura M, Mori Y, Terasaki M, et al. Glucose-dependent insulinotropic polypeptide inhibits cardiac hypertrophy and fibrosis in diabetic mice via suppression of TGF-β2. Diab Vasc Dis Res. 2021 Mar-Apr;18(2):1479164121999034.
[6] English A, Craig SL, Flatt PR, et al. Individual and combined effects of GIP and xenin on differentiation, glucose uptake and lipolysis in 3T3-L1 adipocytes. Biol Chem. 2020 Oct 25;401(11):1293-1303.
[7] Vyavahare SS, Mieczkowska A, Flatt PR, et al. GIP analogues augment bone strength by modulating bone composition in diet-induced obesity in mice. Peptides. 2020 Mar;125:170207.
[8] Hölscher C. The incretin hormones glucagonlike peptide 1 and glucose-dependent insulinotropic polypeptide are neuroprotective in mouse models of Alzheimer's disease. Alzheimers Dement. 2014 Feb;10(1 Suppl):S47-54.
(D-Ala2)-GIP (human)是一种葡萄糖依赖性促胰岛素多肽的类似物，可激活GIP受体的活性（EC50=630pM），常用于研究II型糖尿病的治疗方法 [1]。(D-Ala2)-GIP可以抵抗二肽基肽酶-4的降解，从而延长在体内的作用时间，增强其促进胰岛素分泌的活性[2]。(D-Ala2)-GIP可调节细胞能量代谢、脂肪储存以及β细胞功能[3]。(D-Ala2)-GIP还具有改善肥胖相关胰岛素抵抗和保护β细胞的潜力[4]。
在体外，(D-Ala2)-GIP (300nM) 预处理小鼠原代心肌细胞1小时，随后以30mM高葡萄糖刺激24小时，显著抑制NADPH oxidase驱动的超氧化物生成，同时降低心肌肥厚标志物β-Mhc及纤维化关键因子Tgf-β2的mRNA表达水平[5]。(D-Ala2)-GIP（1μM）预处理3T3-L1前脂肪细胞96小时，显著促进脂肪细胞分化和脂质积累，同时上调脂蛋白脂肪酶（Lpl）和脂肪酸合酶（Fasn）的基因表达[6]。
在体内，(D-Ala2)-GIP（25nmol/kg）每日腹腔注射一次，持续42天，用于处理高脂饮食诱导的肥胖预糖尿病瑞士NIH小鼠。(D-Ala2)-GIP显著降低了非空腹血糖水平，并改善了葡萄糖耐量[7]。(D-Ala2)-GIP（25nmol/kg）每日一次腹腔注射，用于处理APPswe/PS1阿尔茨海默病模型小鼠，持续8周。(D-Ala2)-GIP显著改善了小鼠的空间记忆和突触可塑性，增加了海马区突触数量，减少了淀粉样斑块负荷和神经炎症反应，并增强了齿状回的神经祖细胞增殖[8]。
| Cell experiment [1]: | |
Cell lines | 3T3-L1 pre-adipocytes (mouse embryonic fibroblast cell line) |
Preparation Method | 3T3-L1 pre-adipocytes were maintained in Dulbecco's minimal essential medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and antibiotics (100U/mL penicillin and 100μg/mL streptomycin) at 37°C, 5% CO₂. Differentiation was induced post-confluence using a cocktail (1μg/mL insulin, 1μM dexamethasone, 0.5mM isobutyl-1-methylxanthine) with or without 1μM (D-Ala2)-GIP. The differentiation medium was replenished every two days. |
Reaction Conditions | 1μM; 12-day differentiation period |
Applications | (D-Ala2)-GIP significantly enhanced adipocyte differentiation and lipid accumulation, as evidenced by increased Oil-red O staining. (D-Ala2)-GIP upregulated key adipogenic genes (Lpl, Fasn, Atgl) and lipolytic genes (Hsl), and stimulated glycerol release in mature adipocytes. |
| Animal experiment [2]: | |
Animal models | High-fat-fed (HFF) Swiss NIH mice (diet-induced obesity model) |
Preparation Method | Obese-prediabetic mice received daily intraperitoneal injections of (D-Ala2)-GIP (25nmol/kg) for 42 consecutive days. Body weight and non-fasting blood glucose were monitored regularly. An intraperitoneal glucose tolerance test (18mmol/kg) was performed on day 43 after an 18-hour fast. |
Dosage form | 25nmol/kg; i.p. |
Applications | (D-Ala2)-GIP significantly reduced non-fasting blood glucose levels and improved glucose tolerance during the glucose challenge. (D-Ala2)-GIP enhanced bone strength by increasing ultimate load and work-to-fracture without altering trabecular or cortical bone microarchitecture. (D-Ala2)-GIP improved bone composition by increasing collagen maturity (enzymatic cross-linking) and mineral-to-matrix ratio while reducing heterogeneity in mineral crystallite size. |
References: | |
| Cas No. | 444073-04-5 | SDF | |
| 别名 | D-ALA2]-GIP(HUMAN)-胃抑素 | ||
| 分子式 | C226H338N60O66S | 分子量 | 4983.53 |
| 溶解度 | DMSO : 50 mg/mL (10.03 mM; Need ultrasonic) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 200.7 μL | 1.0033 mL | 2.0066 mL |
| 5 mM | 40.1 μL | 200.7 μL | 401.3 μL |
| 10 mM | 20.1 μL | 100.3 μL | 200.7 μL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet